Literature DB >> 6116512

Effects of a potent and specific beta 2-adrenoceptor antagonist on intraocular pressure.

J A Nathanson.   

Abstract

1 Physiological studies support the possibility of adrenergic regulation of aqueous humor secretion from the ciliary process, a tissue which has recently been shown to contain a predominance of beta 2-adrenoceptors. 2 The present experiments examine the effects of a potent and highly specific beta 2-antagonist (IPS 339) on intraocular pressure in the normal rabbit eye. 3 The observed decrease in pressure caused by IPS 339 suggests that highly specific beta 2-antagonists may be useful in decreasing elevated intraocular pressure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116512      PMCID: PMC2071848          DOI: 10.1111/j.1476-5381.1981.tb16776.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  A potent new beta2-adrenoceptor blocking agent.

Authors:  J L Imbs; F Miesch; J Schwartz; J Velly; G Leclerc; A Mann; C G Wermuth
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

2.  In vitro determination of the ability of drugs to bind to adrenergic receptors.

Authors:  A H Neufeld; E D Page
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-12       Impact factor: 4.799

3.  The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung in vitro.

Authors:  K P Minneman; L R Hegstrand; P B Molinoff
Journal:  Mol Pharmacol       Date:  1979-07       Impact factor: 4.436

Review 4.  The beta-adrenergic blocking agents and the treatment of glaucoma.

Authors:  T J Zimmerman; W P Boger
Journal:  Surv Ophthalmol       Date:  1979 May-Jun       Impact factor: 6.048

5.  Adrenergic drugs and intraocular pressure: effects of selective beta-adrenergic agonists.

Authors:  D E Potter; J M Rowland
Journal:  Exp Eye Res       Date:  1978-12       Impact factor: 3.467

6.  Some characteristics of an adenyl cyclase preparation from rabbit ciliary process tissue.

Authors:  M B Waitzman; W D Woods
Journal:  Exp Eye Res       Date:  1971-07       Impact factor: 3.467

7.  Beta-adrenergic responses in the eyes of rabbits, primates, and man.

Authors:  M E Langham; E Diggs
Journal:  Exp Eye Res       Date:  1974-09       Impact factor: 3.467

8.  Drug therapy of glaucoma.

Authors:  G D Paterson; G Paterson
Journal:  Br J Ophthalmol       Date:  1972-03       Impact factor: 4.638

9.  Effects of catecholamines on the ocular tension of normal and sympathetically denervated rabbit eyes.

Authors:  P Bhattacherjee
Journal:  Exp Eye Res       Date:  1971-07       Impact factor: 3.467

Review 10.  Experimental studies on the mechanism of action of timolol.

Authors:  A H Neufeld
Journal:  Surv Ophthalmol       Date:  1979 May-Jun       Impact factor: 6.048

View more
  6 in total

1.  Neodymium-YAG transscleral cyclocoagulation in rabbit eyes.

Authors:  R G Devenyi; G E Trope; W S Hunter; W H Hunter
Journal:  Br J Ophthalmol       Date:  1987-06       Impact factor: 4.638

2.  beta-Adrenergic receptor subtypes and intraocular pressure.

Authors:  A Rushton
Journal:  Br J Ophthalmol       Date:  1983-08       Impact factor: 4.638

3.  The role of beta 2-adrenoceptors in the IOP-lowering effect of adrenaline.

Authors:  H C Innemee; P A van Zwieten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

4.  Beta adrenergic receptors in pigmented ciliary processes.

Authors:  G E Trope; B Clark
Journal:  Br J Ophthalmol       Date:  1982-12       Impact factor: 4.638

5.  Beta-adrenergic receptor subtypes in iris-ciliary body of rabbits.

Authors:  C J Schmitt; D M Gross; N N Share
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

6.  ICI 118,551: an effective ocular hypotensive agent with selectivity for the ciliary process beta 2-adrenoceptor and with minimal cardiac side effects.

Authors:  J A Nathanson
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.